Aurora Innovation CEO Says Apple, Microsoft Takeover ‘potentially Appealing

– Blooomberg

– Blooomberg

Total
0
Shares
Related Posts
Read More

Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study

Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to 

KRON